UroGen Pharma
Develops localized mitomycin therapies for low-grade urothelial cancers.
$43.62
After-hours close−0.01 (−0.02%)
At close$43.63(−4.11%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 95.32%46.44M sharesInsiders 0.26%128.7K sharesOther 4.42%2.15M shares
Shares outstanding 48.72M · Float 43.34M · 89.0% free float
Institutions13F, as of Mar 31, 2026
179 holders · 46.44M shares · 31 new positions · 84 increased · 48 reduced · 27 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 4.54M | 9.33% | 0 | May 15, 2026 |
| BlackRock, Inc. | 2.85M | 5.84% | +244.6K | May 13, 2026 |
| Toronto Dominion Bank | 2.62M | 5.37% | +2.62M | May 15, 2026 |
| Morgan Stanley | 2.56M | 5.25% | −2.9K | May 15, 2026 |
| Kynam Capital Management, LP | 2.25M | 4.61% | +2.25M | May 15, 2026 |
| Jefferies Financial Group Inc. | 2.20M | 4.51% | 0 | May 8, 2026 |
| Paradigm Biocapital Advisors LP | 1.70M | 3.50% | −2.77M | May 15, 2026 |
| Acorn Capital Advisors, LLC | 1.67M | 3.43% | +225.0K | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Phillip Grossincl. Adage Capital Management, L.P., Robert Atchinson | 8.87% | 3.74M | 13G | Nov 12, 2024 ↗ |
| BlackRock, Inc. | 5.90% | 2.50M | Nov 8, 2024 ↗ | |
| The Toronto-Dominion Bank | 5.40% | 2.62M | 13G | May 15, 2026 ↗ |
| Morgan Stanley | 5.40% | 2.49M | 13G | Aug 6, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Mark Schoenberg | officer: Chief Medical Officer | 59.1K | 0.12% | Aug 24, 2026 |
| Jason Drew Smith | officer: General Counsel | 51.3K | 0.11% | Feb 11, 2026 |
| James A. Jr. Robinson | director | 8.0K | 0.02% | Aug 28, 2026 |
| Chris Degnan | officer: Chief Financial Officer | 2.3K | 0.00% | Oct 9, 2025 |
| Cynthia M. Butitta | director | 2.0K | 0.00% | Dec 1, 2025 |
| Stuart Holden | director | 2.0K | 0.00% | Dec 1, 2025 |
| Leana Wen | director | 2.0K | 0.00% | Dec 1, 2025 |
| Daniel George Wildman | director | 2.0K | 0.00% | Dec 1, 2025 |
10 people have not refiled in the last 18 months (3.62M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 20, 2026 | Mark Schoenbergofficer: Chief Medical Officer | Sale | 60,677 | $47.05 | 59,086 |
| Jul 9, 2026 | Mark Schoenbergofficer: Chief Medical Officer | Sale | 10,000 | $40.00 | 119,763 |
| Jun 22, 2026 | Mark Schoenbergofficer: Chief Medical Officer | Sale | 10,000 | $35.01 | 129,763 |
| Jun 8, 2026 | Mark Schoenbergofficer: Chief Medical Officer | Sale | 5,222 | $27.30 | 139,763 |
| May 8, 2026 | Mark Schoenbergofficer: Chief Medical Officer | Sale | 10,000 | $30.00 | 134,985 |
| Feb 3, 2026 | Jason Drew Smithofficer: General Counsel | Sale · 3 lots | 7,479 | $19.69 | 51,326 |
| Feb 3, 2026 | Mark Schoenbergofficer: Chief Medical Officer | Sale · 3 lots | 7,373 | $19.69 | 144,985 |
| Nov 19, 2025 | Mark Schoenbergofficer: Chief Medical Officer | Sale | 10,000 | $25.00 | 139,025 |
| Oct 8, 2025 | Chris Degnanofficer: Chief Financial Officer | Sale | 2,203 | $16.85 | 2,280 |
| Sep 8, 2025 | Jason Drew Smithofficer: General Counsel | Sale | 1,520 | $19.11 | 43,305 |
CongressHouse and Senate disclosures
Not reported.